CUMBERLAND PHARMACEUTICALS INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $36.0M |
| Operating income | -$2.8M | -$6.4M | -$9.6M | -$5.7M | -$7.7M |
| Cost of revenue | $6.7M | $6.6M | $6.1M | $9.1M | $8.8M |
| Cash from operations | $4.9M | -$612,186 | $6.1M | $8.5M | $6.3M |
| Capital expenditure | $97,903 | $66,461 | $281,268 | $102,148 | $103,532 |
| Free cash flow | $4.8M | -$678,647 | $5.8M | $8.4M | $6.2M |
| Share repurchases | $263,478 | $579,049 | $740,533 | $1.1M | $1.4M |
| Impairments | — | $400,000 | $0 | $0 | $0 |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M |
Shares outstanding 15.0M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.